Scientists identify how virus triggers cervical and mouth cancer

December 14, 2010

University of Manchester scientists have discovered for the first time an important new way in which the human papilloma virus (HPV) triggers cancer in what could lead to new treatments for cervical and mouth cancer.

HPV infection is known to increase the risk of developing cancers of the cervix and mouth with the two high-risk forms of the virus accounting for approximately 70% of all cervical cancer cases.

Vaccinations against these high-risk forms of HPV should reduce the incidence of but the frequency of mouth cancer actually increased in the UK by about 50% between 1989 and 2007, a trend that seems to be accelerating.

If the current vaccines prove effective at preventing oral HPV infection, the authors claim their findings provide additional justification for the current programme of vaccinating young girls and may also lend support to extending the programme to young boys too.

"Scientists have known for some years about the link between HPV and certain cancers but the biological processes involved are not fully understood," said Dr Ian Hampson, who with wife Dr Lynne Hampson headed the research. "Our latest results shed new light on this.

"Our study has shown that a protein in called Cdc42, which is already known to be implicated in a number of cancers as well as in tumour spread, is inappropriately activated by the .

"The findings are important since it is essential to increase our understanding of how the virus causes the disease if we are to design new approaches for the prevention or treatment of HPV-related cancers. Mouth cancer, in particular, is notoriously difficult to treat and often leads to long-term disability.

"If the vaccination programme is shown to reduce the incidence of oral HPV infection then this study would appear to support its continued use as a way to prevent HPV-related mouth cancer and perhaps consideration should be given to extending the programme to boys."

The research, published in the British Journal of Cancer, was carried out in the Gynaecological Oncology Laboratories at St Mary's Hospital, Manchester, by one of the Hampsons' PhD students, Dr Anthony Oliver.

Dr Oliver said: "There are literally hundreds of publications describing the potential role of Cdc42 in malignant disease but our work is the first to show that can activate this protein.

"There is already a drive towards developing drugs that target activated Cdc42 and our findings now indicate that these agents may be useful for the treatment of HPV-related cancers too."

More information: 'The HPV16 E6 binding protein Tip-1 interacts with ARHGEF16 which activates Cdc42,' British Journal of Cancer.

Related Stories

Recommended for you

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

New study points the way to therapy for rare cancer that targets the young

November 21, 2017
After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Raveon
not rated yet Dec 14, 2010
"...and perhaps consideration should be given to extending the programme to boys."

And who do they think is most likely to get the infection in the mouth if not men? As is usual, they will wait until there are a lot of mouth cancers before they act. The question I want to know is if the vaccine will do anything for those already with a mouth infection.
winthrom
not rated yet Dec 14, 2010
I agree with Raveon, "The question I want to know is if the vaccine will do anything for those already with a mouth infection". Moreover, does the vaccine protect older folks from getting the infection?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.